Semaglutide for osteoarthritis: Difference between revisions
Created page with "A study published in the ''New England Journal of Medicine'' on October 31st highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain rela..." |
No edit summary Tag: Manual revert |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
A study published in the ''New England Journal of Medicine'' on October | [[File:Areas affected by osteoarthritis.gif|thumb|left|Areas affected by osteoarthritis]] | ||
A recent [https://www.nejm.org/doi/full/10.1056/NEJMoa2403664 study] published in the ''New England Journal of Medicine'' on October 31, 2024, highlights that once-weekly [[semaglutide]] significantly reduces body weight and alleviates pain related to [[knee osteoarthritis]] in individuals with obesity, compared to a placebo. | |||
== Study Overview == | |||
The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, | [[File:Ozempic® 3ml.jpg|thumb|right|Ozempic, a form of semaglutide]] | ||
The study, led by Henning Bliddal, M.D., from [[Copenhagen University Hospital]] at Bispebjerg and Frederiksberg in Denmark, was conducted over 68 weeks at 61 sites across 11 countries. A total of 407 participants with [[obesity]] and clinically confirmed moderate [[knee osteoarthritis]] characterized by moderate to severe pain were enrolled. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on [[physical activity]] and a [[reduced-calorie diet]]. | |||
== Key Findings == | |||
The study results demonstrated the following: | |||
* '''Body Weight Reduction''': By week 68, participants receiving semaglutide experienced a mean body weight reduction of '''−13.7%''', compared to '''−3.2%''' in the placebo group. | * '''Body Weight Reduction''': By week 68, participants receiving semaglutide experienced a mean body weight reduction of '''−13.7%''', compared to '''−3.2%''' in the placebo group. | ||
* '''Pain Reduction''': The mean change in the ''Western Ontario and McMaster Universities Osteoarthritis Index'' (WOMAC) pain score was −41.7 points for the semaglutide group | * '''Pain Reduction''': The mean change in the ''Western Ontario and McMaster Universities Osteoarthritis Index'' ([[WOMAC]]) pain score was −41.7 points for the semaglutide group, compared to −27.5 points for the placebo group. | ||
* '''Improvement in Physical Function''': The 36-Item Short Form Health Survey | * '''Improvement in Physical Function''': The 36-Item Short Form Health Survey ([[SF-36]]) indicated greater improvement in physical function among the semaglutide group, with a mean increase of '''12.0''' points compared to '''6.5''' points in the placebo group. | ||
The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated | The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated. | ||
== References == | == References == | ||
* [https://www.nejm.org/doi/full/10.1056/NEJMoa2403664 NEJM study - Semaglutide for | * [https://www.nejm.org/doi/full/10.1056/NEJMoa2403664 NEJM study - Semaglutide for Osteoarthritis] | ||
{{stub}} | {{stub}} | ||
[[Category:GLP-1 receptor agonists]] | [[Category:GLP-1 receptor agonists]] | ||
| Line 25: | Line 28: | ||
[[Category:Experimental drugs developed for non-alcoholic fatty liver disease]] | [[Category:Experimental drugs developed for non-alcoholic fatty liver disease]] | ||
[[Category:Danish inventions]] | [[Category:Danish inventions]] | ||
{{w8md}} | |||
Latest revision as of 05:32, 4 February 2025
A recent study published in the New England Journal of Medicine on October 31, 2024, highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, compared to a placebo.
Study Overview[edit]
The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, was conducted over 68 weeks at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis characterized by moderate to severe pain were enrolled. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet.
Key Findings[edit]
The study results demonstrated the following:
- Body Weight Reduction: By week 68, participants receiving semaglutide experienced a mean body weight reduction of −13.7%, compared to −3.2% in the placebo group.
- Pain Reduction: The mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score was −41.7 points for the semaglutide group, compared to −27.5 points for the placebo group.
- Improvement in Physical Function: The 36-Item Short Form Health Survey (SF-36) indicated greater improvement in physical function among the semaglutide group, with a mean increase of 12.0 points compared to 6.5 points in the placebo group.
The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated.
References[edit]
 | |
|---|---|
 |
 |
Tired of Being Overweight?[edit]
Achieve lasting results with W8MD's proven weight loss program, trusted by thousands since 2011. Our comprehensive approach tackles weight gain factors like insulin resistance to help you lose weight and keep it off.
Tailored Weight Loss Solutions[edit]
W8MD offers personalized weight loss plans, including FDA-approved medications and GLP-1 injections, such as:
Other options include:
We also offer nutritious, low-glycemic foods and meal replacements to keep you on track.
Convenient Locations[edit]
W8MD provides weight loss services in Brooklyn, New York and Greater Philadelphia, with tailored plans and GLP-1 weight loss injections.
Looking for a weight loss clinic in Brooklyn or weight loss doctors in NYC? W8MD's expert team is here to help.
Weight Loss Doctor in NYC[edit]
Trust W8MD's best weight loss doctors in NYC for personalized solutions, including wiki Physician Weight Loss Program and GLP-1 injections.
W8MD Weight Loss Clinic in Philadelphia[edit]
W8MD in Philadelphia offers FDA-approved medications and weight loss injections. Visit our medical weight loss clinic for expert care.
Find the best weight loss tips in Philadelphia with W8MD.
Take the First Step[edit]
Book your consultation today and start your journey:
- Visit W8MD Official Site
- Check out Yelp reviews
- Schedule via Patient Fusion
Call now for medical weight loss:
- NYC: 718-946-5500
- Philadelphia: 215-676-2334
Explore W8MD's NYC Physician Weight Loss Program now!
- Individual results may vary!
